---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-040388"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-10-21T20:15:17+00:00"
generated_at: "2026-10-21T20:18:56.840981+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FDA approves GSK/Ionis Hibsago (bepirovirsen) for chronic hepatitis B; Ionis earns 10-12% royalties

## Summary
- FDA approved Hibsago (bepirovirsen) for CHB in adults without cirrhosis, on NrtI therapy ≥6 months, with suppressed HBV DNA and HBsAg ≤3000 IU/ml.
- Phase 3 B-Well pooled data: 19% functional cure (233 of 1,220) vs 0 of 614 on placebo; 26% (200 of 768) in patients with HBsAg ≤1000 IU/ml.
- Approval granted under FDA priority review and Breakthrough Therapy Designation; bepirovirsen is also approved in Japan, with more global decisions expected.
- Ionis licensed bepirovirsen to GSK in 2019; already received upfront, license fee and milestone payments, and is eligible for more milestones plus 10-12% tiered royalties.
- CHB affects roughly 1.7 million people in the U.S.; label carries boxed warnings for on-treatment hepatic flares and thrombocytopenia.

## SEC filing metadata
- accession: 0001140361-26-040388
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-10-21T20:15:17+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/0001140361-26-040388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-040388
- JSON: https://secwatch.observer/filing/0001140361-26-040388.json
- Plain text: https://secwatch.observer/filing/0001140361-26-040388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.